Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

A Prognostic Gene Signature for Metastasis-Free Survival of Triple Negative Breast Cancer Patients

Figure 5

The BPMS is prognostic for metastasis-free survival of breast cancer patients with tumors of the basal subtype.

PAM50 was used to categorize breast tumors into (A) Basal (16 BPMS+ patients out of 120 Basal patients, χ2 = 13.7), (B) luminal A (0 BPMS+ patients out of 110 luminal A patients), (C) luminal B (1 BPMS+ patient out of 97 luminal B patients, χ2 = 0.5), (D) HER2 (4 BPMS+ patients out of 67 HER2 patients, χ2 = 0) and (E) normal (3 BPMS+ patients out of 48 Normal patients, χ2 = 0.8) subtypes as indicated. BrCa443 patients were stratified for MFS using the BPMS. Red indicates patient tumors that express the BPMS signature while black indicates patient tumors that do not. Survival curves were generated by Kaplan–Meier analysis, and the indicated P-values were calculated by the log-rank test.

Figure 5

doi: https://doi.org/10.1371/journal.pone.0082125.g005